Compare Tyson Foods, Inc. (TSN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tyson Foods, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Tyson Foods, Inc. trades at $51.77 (market cap $18.39B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.3× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TSN | VRTX | |
|---|---|---|
Market Cap | $18.39B | $134.06B |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $557.96 |
52-Week Low | $50.72 | $376.62 |
Enterprise Value | $25.66B | $128.18B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $52.28, up 1.67% today, but faces bearish technical signals with the stock trading near key support levels. The company reported mixed quarterly results with two beats and one miss in recent quarters, while maintaining modest profitability with 1.03% net margins. Recent news highlights ongoing fraud investigations and reduced 2026 revenue guidance due to beef segment pressures, creating investor uncertainty despite continued institutional buying interest.
The outlook remains cautious with Wall Street maintaining a $69 price target but technical indicators signaling bearish momentum. Investment opportunity exists in the discounted valuation (P/S 0.33) if operational improvements materialize, though risks include ongoing legal scrutiny, commodity price volatility, and execution challenges in the beef business that could pressure near-term performance.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
